Envestnet Asset Management Inc. Sells 41,481 Shares of Progyny, Inc. (NASDAQ:PGNY)

Envestnet Asset Management Inc. reduced its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 288,083 shares of the company's stock after selling 41,481 shares during the quarter. Envestnet Asset Management Inc. owned about 0.34% of Progyny worth $4,969,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in PGNY. Signaturefd LLC boosted its position in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC boosted its position in shares of Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Progyny in the 4th quarter worth approximately $74,000. 94.93% of the stock is owned by institutional investors.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.01 during midday trading on Monday, hitting $22.75. The company had a trading volume of 504,896 shares, compared to its average volume of 1,743,182. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 39.22, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $33.84. The company has a fifty day moving average of $21.92 and a two-hundred day moving average of $19.14.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Bank of America boosted their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.